Dechra Pharmaceuticals Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
Dechra Pharmaceuticals wird ein jährliches Gewinn- und Umsatzwachstum von 62.5% bzw. 7.9% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 89.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 19.8% betragen.
Wichtige Informationen
62.5%
Wachstumsrate der Gewinne
89.8%
EPS-Wachstumsrate
| Pharmaceuticals Gewinnwachstum | 19.6% |
| Wachstumsrate der Einnahmen | 7.9% |
| Zukünftige Eigenkapitalrendite | 19.8% |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 03 Jan 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Dechra Pharmaceuticals (LON:DPH) Takes On Some Risk With Its Use Of Debt
May 31
A Look At The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)
Mar 28We Think Dechra Pharmaceuticals (LON:DPH) Is Taking Some Risk With Its Debt
Mar 02Dechra Pharmaceuticals' (LON:DPH) Dividend Will Be Increased To £0.125
Mar 02Estimating The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)
Dec 09Dechra Pharmaceuticals (LON:DPH) Is Increasing Its Dividend To £0.3289
Oct 06Dechra Pharmaceuticals (LON:DPH) Is Paying Out A Larger Dividend Than Last Year
Sep 22Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At £0.3289
Sep 08Estimating The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)
Aug 18Do Dechra Pharmaceuticals' (LON:DPH) Earnings Warrant Your Attention?
Aug 02These 4 Measures Indicate That Dechra Pharmaceuticals (LON:DPH) Is Using Debt Reasonably Well
Jun 10Calculating The Fair Value Of Dechra Pharmaceuticals PLC (LON:DPH)
May 08Do Dechra Pharmaceuticals's (LON:DPH) Earnings Warrant Your Attention?
Apr 22Dechra Pharmaceuticals (LON:DPH) Is Increasing Its Dividend To UK£0.12
Feb 23Is Dechra Pharmaceuticals PLC (LON:DPH) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 29Is Now The Time To Put Dechra Pharmaceuticals (LON:DPH) On Your Watchlist?
Jan 11Here's Why Dechra Pharmaceuticals (LON:DPH) Can Manage Its Debt Responsibly
Dec 04It Looks Like Shareholders Would Probably Approve Dechra Pharmaceuticals PLC's (LON:DPH) CEO Compensation Package
Oct 15Dechra Pharmaceuticals' (LON:DPH) Upcoming Dividend Will Be Larger Than Last Year's
Sep 25Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At UK£0.29
Sep 11With EPS Growth And More, Dechra Pharmaceuticals (LON:DPH) Is Interesting
Sep 08Is Dechra Pharmaceuticals PLC (LON:DPH) Worth UK£43.4 Based On Its Intrinsic Value?
Jun 17Is Dechra Pharmaceuticals PLC (LON:DPH) A Smart Choice For Dividend Investors?
Apr 09Dechra Pharmaceuticals (LON:DPH) Has A Pretty Healthy Balance Sheet
Mar 05Are Dechra Pharmaceuticals' (LON:DPH) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Feb 17
Dechra Pharmaceuticals PLC (LON:DPH) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?
Feb 02Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 6/30/2026 | 954 | 187 | N/A | N/A | 1 |
| 6/30/2025 | 904 | 123 | 160 | 182 | 5 |
| 6/30/2024 | 837 | 102 | 142 | 163 | 2 |
| 6/30/2023 | 762 | -28 | 33 | 64 | N/A |
| 3/31/2023 | 744 | 6 | 39 | 75 | N/A |
| 12/31/2022 | 727 | 40 | 45 | 86 | N/A |
| 9/30/2022 | 704 | 49 | 45 | 105 | N/A |
| 6/30/2022 | 682 | 58 | 45 | 123 | N/A |
| 3/31/2022 | 661 | 66 | 48 | 121 | N/A |
| 12/31/2021 | 641 | 73 | 51 | 119 | N/A |
| 9/30/2021 | 624 | 64 | 3 | 104 | N/A |
| 6/30/2021 | 608 | 56 | -45 | 89 | N/A |
| 3/31/2021 | 587 | 50 | -45 | 102 | N/A |
| 12/31/2020 | 566 | 44 | -44 | 114 | N/A |
| 9/30/2020 | 541 | 39 | 7 | 110 | N/A |
| 6/30/2020 | 515 | 34 | 57 | 106 | N/A |
| 3/31/2020 | 507 | 31 | 57 | 91 | N/A |
| 12/31/2019 | 499 | 29 | 57 | 76 | N/A |
| 9/30/2019 | 490 | 30 | 58 | 79 | N/A |
| 6/30/2019 | 482 | 31 | 59 | 82 | N/A |
| 3/31/2019 | 463 | 28 | 61 | 82 | N/A |
| 12/31/2018 | 444 | 25 | 62 | 81 | N/A |
| 9/30/2018 | 426 | 30 | 57 | 73 | N/A |
| 6/30/2018 | 407 | 36 | 51 | 64 | N/A |
| 3/31/2018 | 394 | 40 | 57 | 69 | N/A |
| 12/31/2017 | 381 | 43 | 63 | 75 | N/A |
| 9/30/2017 | 370 | 35 | 65 | 76 | N/A |
| 6/30/2017 | 359 | 26 | 67 | 77 | N/A |
| 3/31/2017 | 334 | 19 | N/A | 69 | N/A |
| 12/31/2016 | 309 | 11 | N/A | 62 | N/A |
| 9/30/2016 | 278 | 12 | N/A | 53 | N/A |
| 6/30/2016 | 248 | 13 | N/A | 44 | N/A |
| 3/31/2016 | 230 | 17 | N/A | 43 | N/A |
| 12/31/2015 | 213 | 20 | N/A | 42 | N/A |
| 9/30/2015 | 208 | 20 | N/A | 42 | N/A |
| 6/30/2015 | 203 | 19 | N/A | 41 | N/A |
| 3/31/2015 | 201 | 21 | N/A | 41 | N/A |
| 12/31/2014 | 199 | 22 | N/A | 42 | N/A |
| 9/30/2014 | 196 | 21 | N/A | 27 | N/A |
| 6/30/2014 | 194 | 19 | N/A | 11 | N/A |
| 12/31/2013 | 193 | 14 | N/A | 25 | N/A |
| 9/30/2013 | 191 | 13 | N/A | 31 | N/A |
| 6/30/2013 | 189 | 11 | N/A | 37 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: DPH wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (1.5%).
Ertrag vs. Markt: DPH wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.
Hohe Wachstumserträge: DPH wird voraussichtlich in den nächsten 3 Jahren rentabel werden.
Einnahmen vs. Markt: DPHDie Einnahmen des Unternehmens (7.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt UK (3.5% pro Jahr).
Hohe Wachstumseinnahmen: DPHDie Einnahmen des Unternehmens (7.9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: DPHDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (19.8%).